Table 2.
Clinical characteristics and assessment results of study participants.
| Clinical measures | Paclitaxel (n = 29) | Healthy controls (n = 29) | p-value |
|---|---|---|---|
| Age, years | 53.6 ± 12.7 | 52.1 ± 14.0 | 0.27 |
| Gender, female, n (%) | 27 (93%) | 27 (93%) | |
| Cumulative dose, mg | 1492.79 ± 388.93 | ||
| EORTC QLQ-CIPN20 | 19.3 [3.6–31.6] | 0 [0–0] | < 0.001 |
| TNSr | 3 [1–7] | 0 [0–1] | < 0.001 |
| Ocular assessments | |||
| OSDI score | 12.5 [0–28.1] | 0 [0–8.3] | 0.007 |
| OSDI (symptoms) | 2.7 [0–8] | 0 [0–2] | 0.001 |
| OSDI (visual function) | 0.7 [0–2.7] | 0 [0–0.7] | 0.022 |
| OSDI (environment) | 0 [0–4] | 0 [0–1.3] | 0.202 |
| CNFL (mm/mm2) | 14.2 ± 4.0 | 16.4 ± 4.0 | 0.04 |
| IWL (mm/mm2) | 14.4 ± 4.0 | 16.9 ± 4.9 | 0.04 |
| CNFD (no/mm2) | 23.7 ± 7.6 | 27.8 ± 7.4 | 0.08 |
| CNBD (no/mm2) | 34.5 ± 18.8 | 41.3 ± 23.0 | 0.25 |
EORTC QLQ-CIPN20, The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire in Chemotherapy-induced Peripheral Neuropathy Questionnaire scale; TNSr, reduced Total Neuropathy Scale; OSDI, Ocular Surface Disease Index; CNFL, corneal nerve fiber length; IWL, inferior whorl length; CNFD, corneal nerve fiber density; CNBD, corneal nerve branch density.
Data is reported as mean ± standard deviation, or median with interquartile range [Quartile 1–Quartile 2]. The Mann Whitney U test was used to compare the data of the matched groups. Significant results are presented in bold.